<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461460</url>
  </required_header>
  <id_info>
    <org_study_id>1986-029</org_study_id>
    <secondary_id>TR701-115</secondary_id>
    <nct_id>NCT01461460</nct_id>
  </id_info>
  <brief_title>A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects</brief_title>
  <official_title>A Phase 1 Blinded, Placebo-controlled Crossover Study to Evaluate the Effects of Oral TR 701 Free Acid on the Electrocardiogram</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trius Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trius Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of oral TR-701 free acid (FA) versus
      placebo on QTcF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the effects of a single therapeutic (200 mg) and supratherapeutic of oral TR-701
      free acid (FA) versus placebo on QT interval corrected for heart rate using Fridericia's
      formula (QTcF) in healthy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QTcF Change from Baseline</measure>
    <time_frame>24 Hours</time_frame>
    <description>Time-matched, placebo adjusted change from the baseline QTcF (ΔΔQTcF).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TR-701 FA 1200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TR-701 FA 200 mg plus Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 FA 1200 mg</intervention_name>
    <description>6 tablet of T-701 FA</description>
    <arm_group_label>TR-701 FA 1200 mg</arm_group_label>
    <other_name>Tedizolid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin 400 mg</intervention_name>
    <description>1 tablet 400 mg Moxifloxacin</description>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 FA 200 mg plus Placebo</intervention_name>
    <description>1 tablet of TR-701 FA with 5 tablet placebo</description>
    <arm_group_label>TR-701 FA 200 mg plus Placebo</arm_group_label>
    <other_name>Tedizolid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>6 placebo tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects between 18 and 45 years of age, inclusive.

          -  Healthy males and females with no clinically significant abnormalities.

          -  Body mass index ≥18.0 kg/m2 and ≤30.0 kg/m2

        Exclusion Criteria:

          -  Sustained supine systolic blood pressure &gt;140 or &lt;100 mmHg or a diastolic blood
             pressure &gt;90 or &lt;60 mmHg at the Screening and Day 1 Visit.

          -  Abnormal ECG at Screening or Day -1 Visits indicating a second or third-degree
             atrioventricular block, or QRS &gt;110 msec, QTcF &gt;450 msec for males and &gt;470 msec for
             females, PR interval &gt;200 msec, or any rhythm other than sinus rhythm which is
             interpreted by the Investigator as clinically significant - History of unexplained
             infections or current signs of infection

          -  History of risk factors for Torsades de Pointes, including unexplained syncope, known
             Long QT Syndrome, heart failure, myocardial infarction, angina, or clinically
             significant abnormal laboratory assessments including hypokalemia, hypercalcemia,
             hypomagnesemia, or family history of Long QT Syndrome or Brugada Syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe G Prokocimer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Trius Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trius Investigator</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2011</study_first_submitted>
  <study_first_submitted_qc>October 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2011</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Torezolid phosphate</mesh_term>
    <mesh_term>Torezolid</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

